Anti-CD19 universal chimeric antigen receptor T cell therapy (BRL Medicine)

抗CD19通用嵌合抗原受体T细胞疗法 (上海邦耀生物)

Report date: 2026/05/08 20:02:52

Base Information

Drug NameAnti-CD19 universal chimeric antigen receptor T cell therapy (BRL Medicine)
Drug Alias NameAllogeneic Anti-CD19 CAR T cells therapy(Bioray Laboraytories)Allogeneic Chimeric Antigen Receptor T Cell Targeting CD19 Gene(Bioray Laboraytories)BRL-301CD19-UCARTTyU19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19T lymphocyte replacementsImmunologic cytotoxicity
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAntiphospholipid SyndromeAutoimmune DiseasesScleroderma, Systemic +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBRL Medicine Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBRL Medicine Inc
Inactive CompaniesN/A
Active IndicationsAntiphospholipid SyndromeAutoimmune DiseasesScleroderma, Systemic +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A